Free tool
FAERS Monitor: Safyral
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022574 or its brand name (Safyral, Drospirenone, Ethinyl Estradiol, Levomefolate Calcium). Reports on generic versions are filed under their own applications.
Reports
246
Serious
145
59% of reports
Hospitalization
78
Death reported
5
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- injury67
- pulmonary embolism65
- deep vein thrombosis64
- pain45
- emotional distress41
- anxiety33
- general physical health deterioration28
- anhedonia27
- off label use18
- drug dose omission14
- thrombosis13
- metrorrhagia10
- nausea10
- pain in extremity9
- dyspnoea7
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2011 | 24 |
| 2012 | 51 |
| 2013 | 61 |
| 2014 | 56 |
| 2015 | 27 |
| 2016 | 12 |
| 2017 | 6 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2023 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,913 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| anhedoniaSignal | 27 | 87.9 | 61.6 | 2,235 |
| deep vein thrombosisSignal | 64 | 84.3 | 68.3 | 5,195 |
| injurySignal | 67 | 81.6 | 66.5 | 5,264 |
| pulmonary embolismSignal | 65 | 58.5 | 47.5 | 3,631 |
| metrorrhagiaSignal | 10 | 50.2 | 27.3 | 434 |
| emotional distressSignal | 41 | 29.0 | 21.9 | 1,085 |
| general physical health deteriorationSignal | 28 | 20.7 | 14.6 | 508 |
| thrombosisSignal | 13 | 13.8 | 8.1 | 143 |
| anxietySignal | 33 | 9.9 | 7.2 | 259 |
| drug dose omissionSignal | 14 | 7.2 | 4.4 | 70 |
| painSignal | 45 | 6.3 | 4.8 | 200 |
| pain in extremitySignal | 9 | 2.6 | 1.4 | 8 |
| off label use | 18 | 1.8 | 1.1 | 5 |
| nausea | 10 | 1.1 | 0.6 | 0 |
| dyspnoea | 7 | 1.1 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.